Drugs / VNZ/TEZ/D-IVA
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT06299696 Background | Mar → Apr 2024 | cystic fibrosis | Vertex Pharmaceuticals Incorporated | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VNZ/TEZ/D-IVA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06299696 ↗ |
| Route | Oral | “FDC granules for oral administration” NCT06299696 ↗ |